AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
about
SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activationPioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic beta-cell at submaximal glucose concentrationsInsulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetesAdenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapyAcute activation of AMP-activated protein kinase prevents H2O2-induced premature senescence in primary human keratinocytesDeletion of PKCepsilon selectively enhances the amplifying pathways of glucose-stimulated insulin secretion via increased lipolysis in mouse beta-cellsChicoric acid is an antioxidant molecule that stimulates AMP kinase pathway in L6 myotubes and extends lifespan in Caenorhabditis elegansXanthene derivatives increase glucose utilization through activation of LKB1-dependent AMP-activated protein kinaseShort and long-term impact of lipectomy on expression profile of hepatic anabolic genes in rats: a high fat and high cholesterol diet-induced obese modelMalonyl-CoA decarboxylase is present in the cytosolic, mitochondrial and peroxisomal compartments of rat hepatocytesObesogenic high fat western diet induces oxidative stress and apoptosis in rat heartEnergy sensing pathways: Bridging type 2 diabetes and colorectal cancer?Acute hypoxia influences collagen and matrix metalloproteinase expression by human keratoconus cells in vitro.Glucolipotoxicity of the pancreatic beta cell.The influence of Cox-2 and bioactive lipids on hematological cancers.AMPK and SIRT1: a long-standing partnership?AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.AMPK activation: a therapeutic target for type 2 diabetes?Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesityDynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor.Methyl-donor supplementation in obese mice prevents the progression of NAFLD, activates AMPK and decreases acyl-carnitine levels.Role of AMP-activated protein kinase in ferritin H gene expression by resveratrol in human T cells.Inflammation and insulin resistance: an old story with new ideas.Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscleEffects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice.The pathogenesis of prostate cancer: from molecular to metabolic alterations.Endurance training increases LKB1 and MO25 protein but not AMP-activated protein kinase kinase activity in skeletal muscle.Cardiovascular and metabolic effects of Berberine.Reduced oxidative stress contributes to the lipid lowering effects of isoquercitrin in free fatty acids induced hepatocytes.Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathways.Islet beta cell failure in type 2 diabetesDecreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans.Activation of AMP-Activated Protein Kinase Attenuates Tumor Necrosis Factor-α-Induced Lipolysis via Protection of Perilipin in 3T3-L1 Adipocytes.Development of HPLC/fluorescence detection method for chiral resolution of dansylated benzimidazoles derivatives.Activation of AMP-activated protein kinase prevents lipotoxicity in retinal pericytesAMPK inhibition in health and disease.Yhhu981, a novel compound, stimulates fatty acid oxidation via the activation of AMPK and ameliorates lipid metabolism disorder in ob/ob mice.Association between phosphorylated AMP-activated protein kinase and acetyl-CoA carboxylase expression and outcome in patients with squamous cell carcinoma of the head and neck.New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK
P2860
Q24321658-1C727270-F65F-4234-AC2B-CEA113ED8B81Q24642826-61D8B93D-291B-4DEF-A413-F2B291572724Q26866924-7F91D999-C85A-46E5-87EA-24B88A5DAB83Q28068120-C99ACABA-46C0-4051-9481-406FA4AD354FQ28482314-E46D3F2F-8766-4811-A08C-F86AE0E0FECAQ28506519-7804EB9A-4277-46EF-BBD2-2D1F7B3B962EQ28535013-2B0C620F-137C-4F66-B778-04FDBCB45730Q28543206-7F3C0A75-99AE-42A1-80CF-7524C8A44811Q28543388-9328692E-09FA-4AF9-B3F8-465954440FD3Q28567580-99F0A6F2-661B-4874-883E-1B94534E458EQ28573796-C68ADEFE-9554-4208-966A-58ABA21D7489Q30234587-B3487781-EEB1-4246-A558-2F3CFB878477Q33584891-78451E7D-BD9D-443D-BF76-62104BF29CA0Q33665283-5DBBB558-4F12-4F3B-AF85-94D6B60756F7Q33688673-150945F8-F189-4BFB-ADCD-9E53761B40C2Q33783499-4ED9E54A-4B5B-463C-8D60-B2E55DAAD5CCQ33789079-365839D8-084B-427F-B0EF-E74ACDA0C32CQ33810241-3E069D0A-6B62-48EB-B5B3-4C2862D89783Q33824564-F1E85590-3F0F-400C-BDCB-10ADBD007453Q33836878-1F066C43-D911-4B84-95C1-6D538A5CAE12Q33865881-CA6DDD09-F2BF-4F3C-83FF-558D16D01328Q33906456-9BEFF97D-0E80-488F-86F1-8F2A7832B5DAQ33939343-04BC450A-206E-4836-9B3C-B53285E324C8Q33969562-D01B73B5-4A8C-47F4-A55C-278C61212C96Q34002703-AEF26A86-7405-4473-9CD3-321733EC4D59Q34062752-561C18B1-FF71-4AA9-96B8-531550885AECQ34201846-BF44F0AA-F65E-47CE-B1E5-68D1D5BC3B60Q34338361-1C8BB9EC-BCAA-48DE-80AC-D84346AF5FBFQ34390654-315B78E2-C60C-4BDF-B2E5-5C389FD98321Q34488103-CE3B9BA6-801C-4324-8334-B15D4AF28C6BQ34615384-B40B9F46-8813-4EFD-BD3F-45252B07F786Q34698810-F48B5B97-4AEF-48D3-8A90-481140075585Q34703328-60F6595B-89B0-4509-9ABC-30D9988F95D6Q34839812-721FCE40-D252-45EE-B655-87E8E23D8B03Q34844220-142C5079-1431-4DF2-A1A4-2D734D96CA42Q35027646-0E0B02D3-8EBA-4214-AD7A-78715CB8BC5DQ35094436-7B47ABE2-2E0F-412C-9616-158C59896B6EQ35148203-3814D6C7-607A-47BE-A086-C5DCF2B2BDBAQ35158141-332C4673-EDE2-4BDF-BB4D-6C2F4101B7AEQ35222084-851AA1CB-751B-437F-B3DE-29547917F24F
P2860
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@ast
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@en
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@nl
type
label
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@ast
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@en
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@nl
prefLabel
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@ast
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@en
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@nl
P2860
P356
P1476
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.
@en
P2093
Marc Prentki
P2860
P2888
P304
P356
10.1038/NRD1344
P577
2004-04-01T00:00:00Z
P6179
1023578785